E2Bio Co., Ltd. (CEO Tae-yoon Cho) announced on the 9th that it signed a memorandum of understanding (MOU) with Red One Technology Co., Ltd., Korea Research Institute of Life Sciences Co., Ltd., and Duzen Bio Co., Ltd. in the Duzen Bio conference room to establish a joint venture for joint research and global commercialization of domestic native plants and marine natural materials.
This agreement aims to develop functional products based on scientific verification of indigenous materials such as Palseoncho and Samogasari, and to generate tangible business results in domestic and international markets.
At the signing ceremony, practical plans for each stage, starting with ensuring a stable supply of raw materials and extending to research, production, and distribution, were discussed. Specifically, practical cooperation tasks were shared, such as ensuring uniformity in material composition and developing global standards to address technical regulations required during overseas exports. The participating companies agreed to pursue a joint business model beyond simple technical cooperation by establishing a joint venture.
The collaborative system operates by linking the specialized infrastructure of each company. Red One Technology, leveraging its resource acquisition infrastructure, is responsible for raw material ingredient analysis and lot-by-lot uniformity verification. It also develops raw material specifications that meet global standards and conducts formulation stability assessments. Duzen Bio builds data on anti-inflammatory and antioxidant effects and mechanisms of action through cell-based efficacy verification and skin barrier biomarker analysis. The Korea Research Institute of Life Sciences (KRIBS), leveraging its extensive patent portfolio, new technology certification capabilities, and GMP facilities, is responsible for product licensing and manufacturing processes.
As the lead developer, E2Bio will oversee product planning and marketing, leveraging its established domestic and international distribution network to drive overall commercialization, including global market entry and brand expansion. E2Bio CEO Cho Tae-yoon stated, "The commercialization process, which connects research findings to competitive products in the global market, is crucial. We will demonstrate the commercial value of domestically grown materials based on objective data and certified processes."
- See more related articles
You must be logged in to post a comment.